Tokyo, Japan – [Insert Date] – Takeda Pharmaceutical Company Limited (TSE: 4502; NYSE: TAK) is set to advance its novel tyrosine kinase 2 (TYK2) inhibitor, zasocitinib, towards regulatory approval for the treatment of plaque psoriasis (PsO) following compelling results from its Phase III LATITUDE Atlas study. In a significant head-to-head trial, zasocitinib demonstrated statistically superior efficacy compared to Bristol Myers Squibb’s Sotyktu (deucravacitinib) in adults with moderate-to-severe plaque psoriasis, marking a pivotal moment in Takeda’s strategy to capture a substantial share of the rapidly expanding psoriasis market.
The announcement signals Takeda’s aggressive pursuit of a market projected to be worth $11.56 billion by 2030 across seven major global markets, according to insights from GlobalData. This pivotal trial, alongside data from two other pivotal Phase III LATITUDE trials, forms the bedrock of Takeda’s forthcoming New Drug Application (NDA) submissions to regulatory authorities, including the U.S. Food and Drug Administration (FDA), anticipated to commence within the current fiscal year.
Zasocitinib Outperforms Competitor in Landmark Head-to-Head Study
The LATITUDE Atlas study (NCT06973291), a Phase III head-to-head trial, pitted Takeda’s zasocitinib against Bristol Myers Squibb’s Sotyktu, an established oral TYK2 inhibitor. The results unequivocally showcased zasocitinib’s superior performance, particularly in achieving the primary endpoint: the Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. This critical measure signifies complete skin clearance for patients.
Significantly, over 35% of patients treated with zasocitinib achieved PASI 100 at week 16. This remarkable outcome was more than 2.5 times higher than the response rate observed with Sotyktu, underscoring zasocitinib’s potent efficacy in clearing psoriatic lesions.
Beyond the primary endpoint, zasocitinib also demonstrated statistically significant superiority across all key secondary endpoints evaluated at week 16. These included the PASI 90 response rate, indicating at least a 90% reduction in psoriasis severity, and the Static Physician’s Global Assessment (sPGA) score of 0 (indicating clear skin) or 1 (almost clear). These comprehensive results paint a picture of zasocitinib as a highly effective treatment option for patients seeking substantial and rapid improvement in their condition.
A Consistent and Favorable Safety Profile
Crucially, zasocitinib was found to be generally well-tolerated throughout the LATITUDE Atlas study. The drug exhibited a consistent safety and tolerability profile, with no new safety signals emerging during the trial. This reassuring safety data is paramount for an oral medication intended for chronic disease management, offering physicians confidence in prescribing zasocitinib for long-term patient care.
Dr. Linda Stein Gold, Director of Dermatology Clinical Research at Henry Ford Health and principal investigator for the LATITUDE Atlas study, expressed optimism about the findings. "As expectations for oral therapies continue to rise, these findings support the potential of zasocitinib to help transform what patients and physicians can expect from an oral option in plaque psoriasis," she stated. Her endorsement highlights the clinical significance of zasocitinib’s performance and its potential to redefine treatment paradigms.
Building on a Foundation of Robust Phase III Data
The compelling results from the LATITUDE Atlas study are further bolstered by data from two other pivotal Phase III LATITUDE PsO trials: LATITUDE PsO 3001 (NCT06088043) and LATITUDE PsO 3002 (NCT06108544). These trials provided additional robust evidence of zasocitinib’s efficacy and safety profile.
In the LATITUDE PsO 3001 trial, zasocitinib demonstrated remarkable success in achieving clear or almost clear skin. More than half of the patients treated with zasocitinib achieved this key measure of treatment success at week 16. Specifically, 71.4% of patients treated with zasocitinib achieved an sPGA score of 0/1, a significant improvement compared to only 10.7% of placebo patients and 32.1% of patients treated with Amgen’s Otezla (apremilast) after 16 weeks. Furthermore, zasocitinib achieved a PASI 90 response in 61.3% of patients, a stark contrast to the 5% seen in the placebo group and 16.8% in the Otezla arm.
The LATITUDE PsO 3002 trial echoed these positive outcomes. In this study, 69.2% of patients treated with zasocitinib achieved an sPGA score of 0/1, compared to 12.6% on placebo and 29.7% on Otezla. The PASI 90 response was achieved by 51.9% of zasocitinib-treated patients, significantly outperforming placebo (4%) and Otezla (15.9%).
These comparative data against Otezla, a well-established PDE4 inhibitor for PsO treatment, further solidify zasocitinib’s potential as a differentiated and highly effective oral therapy.
The Evolving Landscape of Psoriasis Treatment
Plaque psoriasis is a chronic, systemic immune-mediated inflammatory disease that significantly impacts patients’ physical, emotional, and psychological well-being. Characterized by itchy, painful, disfiguring, and disabling skin lesions, PsO affects an estimated 64 million people globally, with plaque psoriasis accounting for 80%-90% of all cases.
The current psoriasis market is highly competitive, with several innovative therapies vying for patient and physician attention. Bristol Myers Squibb’s Sotyktu, an oral small molecule TYK2 inhibitor, and AbbVie’s Skyrizi (risankizumab), a blockbuster injectable IL-23 inhibitor, currently hold dominant positions in the U.S. market.
Takeda’s entry with zasocitinib, another TYK2 inhibitor, promises to introduce a new dimension of competition, particularly in the oral therapy segment. The head-to-head superiority demonstrated against Sotyktu suggests zasocitinib could offer a significant advantage for patients seeking optimal disease control with an oral medication.
Furthermore, the landscape is set for further evolution with Johnson & Johnson’s (J&J) Icotyde (icotrokinra), which received FDA approval in March 2026. Icotyde is positioned as the first and only targeted oral peptide designed to precisely block the IL-23 receptor, offering a novel mechanism of action. It is poised to succeed J&J’s Stelara (ustekinumab), an IL-23 inhibitor that lost patent exclusivity in early 2025. J&J also markets the injectable IL-23 inhibitor Tremfya (guselkumab).
Market Projections and Takeda’s Strategic Outlook
The projected growth of the psoriasis market underscores the significant unmet need and the substantial commercial opportunity. GlobalData’s prediction of $11.56 billion in PsO drug sales across the seven major markets by 2030 highlights the immense value and innovation within this therapeutic area.
Takeda’s strategic focus on developing zasocitinib, an oral TYK2 inhibitor, aligns with the growing preference for convenient and effective oral treatment options. The company’s proactive approach to gathering robust clinical data, including head-to-head comparative studies, demonstrates a commitment to positioning zasocitinib as a leading therapy.
The forthcoming regulatory submissions for plaque psoriasis are a critical step in Takeda’s broader pipeline development and its ambition to become a leader in immunology. The success of zasocitinib in these pivotal trials not only strengthens Takeda’s position in the PsO market but also validates its investment in innovative oral therapies that can significantly improve the lives of patients suffering from chronic inflammatory diseases.
The company’s ability to translate these strong clinical outcomes into successful regulatory approvals and market penetration will be closely watched by investors, healthcare providers, and patient advocacy groups alike. With a clear path towards regulatory review and a promising efficacy and safety profile, zasocitinib is poised to become a significant new contender in the fight against plaque psoriasis.
About the Author
